Schrödinger 10-Q: Q3 Revenue Up 19% to $64.5M, $373M Cash, Novartis Deal Amended
SDGR has more than doubled off its 52-week low of $10.945.
Summary
Schrödinger's Q3 10-Q shows revenue up 19% to $64.5M with drug discovery nearly doubling, a wider net loss driven by a non-cash investment markdown, and $373.4M in cash funding at least 24 months of operations.
Key Events · Earnings and Guidance · SDGR
-
Q3 Revenue Grows 19% to $64.5M
Total revenue rose to $64.5M from $54.3M, with drug discovery revenue nearly doubling to $24.2M from $13.0M on a $12.0M Structure Therapeutics collaboration milestone.
-
Net Loss Widens on Non-Cash Mark
Net loss was $37.7M versus $32.8M, driven by a $14.8M non-cash change in fair value of equity investments (Structure Therapeutics); operating loss narrowed to $26.1M from $45.9M as opex fell 13% to $64.4M.
-
$373.4M Cash, 24-Month Runway
Cash, cash equivalents, restricted cash and marketable securities totaled $373.4M at September 30, 2026, which management says funds operations for at least the next 24 months; nine-month operating cash use was $96.5M.
-
Novartis Collaboration Amended
A September 14, 2026 amendment replaces certain collaboration programs with two new programs; total eligible milestones remain up to $1.424B ($704.0M discovery/development, $720.0M commercial).
Analysis · SDGR · Life Sciences
Full financials behind the same-day earnings 8-K confirm Q3 revenue of $64.5M (+19%), with drug discovery revenue nearly doubling to $24.2M on a $12.0M Structure Therapeutics milestone. The headline net loss widened to $37.7M from $32.8M, but that reflects a $14.8M non-cash mark-to-market swing on the Structure Therapeutics stake rather than operating deterioration; operating expenses actually fell 13% to $64.4M and the operating loss narrowed to $26.1M from $45.9M. With cash and securities of $373.4M, the company funds at least 24 months of operations, so there is no near-term financing need despite $96.5M of operating cash burned in nine months. Two new disclosures matter for the pipeline: the September Novartis amendment swaps certain programs for two new ones while keeping up to $1.424B in milestones, and the Tectora out-licensing of two early-stage programs brought an equity stake rather than cash.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SDGR was trading at $31.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.95 to $33.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.